secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-278827
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa prices $250M public offering of 11.6M ADSs at $21.50 per ADS
---------------------------------------------------------------------

- Priced 11,627,907 ADSs at $21.50 each; gross proceeds ~$250M; net proceeds ~$234.4M.
- Underwriters granted 30-day option to purchase up to 1,744,186 additional ADSs.
- Offering expected to close November 14, 2025; proceeds to fund product development and general corporate purposes.
- Existing cash plus net proceeds expected to fund operating expenses into 2028.
- Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312525278827/0001193125-25-278827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312525278827/d39112d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-278827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer